Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Perphenazine
Drug ID BADD_D01743
Description An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine.
Indications and Usage For use in the management of the manifestations of psychotic disorders and for the control of severe nausea and vomiting in adults.
Marketing Status approved
ATC Code N05AB03
DrugBank ID DB00850
KEGG ID D00503
MeSH ID D010546
PubChem ID 4748
TTD Drug ID D02HED
NDC Product Code 42973-165; 51407-697; 68084-607; 68382-592; 0781-8049; 23155-800; 23155-802; 51407-694; 70518-0710; 70518-2639; 70518-3106; 0904-6599; 63629-2248; 63629-2249; 63629-2250; 70518-0940; 70518-2985; 70518-3257; 70771-1042; 64980-290; 70518-0458; 70518-0731; 70518-1739; 70518-3108; 0591-4103; 0781-8047; 52536-164; 64980-291; 64980-292; 64980-293; 68382-593; 70518-1125; 71205-842; 0591-4102; 0603-5060; 0603-5061; 0904-6600; 52536-168; 63629-2251; 63629-2253; 70518-3121; 71205-843; 23155-801; 52536-162; 52536-170; 68084-602; 70771-1041; 71205-844; 0591-4101; 23155-799; 53808-1124; 70518-3033; 0904-6601; 46204-0003; 51407-696; 63629-2252; 68382-591; 70771-1044; 71205-841; 0603-5062; 0603-5063; 0781-8046; 0781-8048; 0591-4104; 68382-594; 70518-2890; 70771-1043; 65372-1191; 51407-695
UNII FTA7XXY4EZ
Synonyms Perphenazine | Perfenazine | Chlorpiprazine | Trilafon
Chemical Information
Molecular Formula C21H26ClN3OS
CAS Registry Number 58-39-9
SMILES C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abnormal dreams17.15.02.001; 19.02.03.001---
Agitation17.02.05.012; 19.06.02.001--
Agranulocytosis01.02.03.001---
Akathisia17.01.02.002; 19.06.02.006--
Amenorrhoea05.05.01.002; 21.01.02.001--
Anaphylactic shock10.01.07.002; 24.06.02.004---
Anaphylactoid reaction10.01.07.003; 24.06.03.007---
Angioedema10.01.05.009; 22.04.02.008; 23.04.01.001---
Asphyxia12.01.08.011; 22.02.02.001---
Asthma10.01.03.010; 22.03.01.002---
Ataxia08.01.02.004; 17.02.02.001--
Body temperature increased13.15.01.001---
Bradycardia02.03.02.002---
Breast enlargement21.05.04.001---
Cardiac arrest02.03.04.001--
Cataract06.06.01.001--
Catatonia19.11.01.001---
Cholestasis09.01.01.001---
Circulatory collapse24.06.02.001---
Confusional state17.02.03.005; 19.13.01.001--
Constipation07.02.02.001--
Cough22.02.03.001--
CSF protein abnormal13.07.02.004---
Death08.04.01.001--
Dermatitis contact10.01.01.003; 12.03.01.040; 23.03.04.004---
Dermatitis exfoliative10.01.01.004; 23.03.07.001--
Diarrhoea07.02.01.001--
Disorientation17.02.05.015; 19.13.01.002---
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.007--
Dry mouth07.06.01.002--
The 1th Page    1 2 3 4 5    Next   Last    Total 6 Pages